Pfizer shares the ADC data that convinced it to start a Phase 3 lung cancer trial
23 May 2024
ADCClinical ResultPhase 3Phase 1
When Pfizer laid out the ambitious vision for its new oncology division in February, it announced that it was taking the antibody-drug conjugate sigvotatug vedotin
directly from Phase 1 to Phase 3
. Now the drugmaker is releasing the updated data that convinced it to accelerate the drug acquired from its $43 billion deal for Seagen last year.
In updated results released Thursday, Pfizer said that about one-fifth of lung cancer patients who received sigvotatug vedotin saw their tumors shrink by at least 30%. And in 40 patients with non-squamous, non-small cell lung cancer, which includes forms of lung cancer that typically start from the periphery of the lungs, 13 patients saw their tumors shrink by at least that amount, a 32.5% response rate.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.